Li Yexiong

[Expert Profile] Li Yexiong, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in radiation oncology in China, working in the Department of Radiation Oncology, Cancer Hospital of the Chinese Academy of Medical Sciences. He has long been dedicated to radiation therapy and comprehensive treatment of NK/T-cell lymphoma and difficult lymphomas, and is a leading figure in lymphoma radiation therapy in China.

[Education & Career] Professor Li Yexiong graduated from a renowned medical university, completed systematic radiation oncology and oncology training at the Cancer Hospital of the Chinese Academy of Medical Sciences, and further studied at famous international cancer centers, systematically mastering cutting-edge international precision radiation therapy techniques. He has long served as Director of the Department of Radiation Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences, holding important academic positions including Chair of the Radiation Oncology Branch of the Chinese Medical Association. He has presided over grants from the National Natural Science Foundation of China and the National Key R&D Program, and is a discipline leader in the field of radiation oncology in China.

[Areas of Expertise] Professor Li specializes in radiation therapy and comprehensive treatment of hematologic malignancies such as NK/T-cell lymphoma, Hodgkin lymphoma, and non-Hodgkin lymphoma, as well as precise radiation therapy for various difficult tumors. He has profound expertise in the application of precision techniques such as involved-field radiotherapy, intensity-modulated radiation therapy (IMRT), and image-guided radiation therapy (IGRT) for lymphoma. He excels at developing individualized radiation therapy plans based on different lymphoma subtypes and stages, skillfully combining radiation therapy with chemotherapy and immunotherapy, helping numerous lymphoma patients achieve curative treatment while maximizing protection of normal tissues.

[Academic Achievements & Industry Contributions] Professor Li has achieved internationally leading results in the field of NK/T-cell lymphoma radiation therapy, leading multiple prospective clinical studies that established a radiotherapy-centered comprehensive treatment model for early-stage NK/T-cell lymphoma, significantly improving patient survival rates. His research findings have been published in top international oncology journals and widely cited by international guidelines. He has led the development of Chinese lymphoma radiation therapy guidelines and expert consensus statements, actively promoted the standardized application of precision radiation therapy techniques in the field of lymphoma, and organized nationwide radiation oncology specialist training and multi-center collaborative research, making outstanding contributions to the development of radiation oncology as a discipline in China.

[Clinical Practice & Outstanding Contributions] For decades on the radiation therapy clinical front lines, Professor Li has treated tens of thousands of patients with lymphoma and various tumors, successfully implementing precise and safe radiation therapy for numerous patients. Leading his team, he has established a comprehensive lymphoma radiation therapy quality control system, with his precision radiation therapy techniques and standardized management becoming a national benchmark. He has been repeatedly recognized as an outstanding discipline leader, trained a large number of radiation oncology professionals, and is deeply trusted by patients and respected by peers alike. He is an authoritative expert in the field of radiation oncology in China.

[Honors & Reputation] Professor Li Yexiong serves as Vice Chair of the Radiation Oncology Branch of the Chinese Medical Association and Director of the Department of Radiation Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences, among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is an authoritative expert in the field of radiation oncology in China. He has profound expertise in radiation therapy of NK/T-cell lymphoma and difficult lymphomas. He has led research on precision lymphoma radiation therapy, systematically optimizing radiation target volumes and dose regimens, with findings published in international authoritative journals and receiving multiple science and technology awards. He has participated in the development of multiple lymphoma radiation therapy guidelines. For decades on the clinical front lines, he has helped numerous lymphoma patients gain curative treatment opportunities through precision radiation therapy, and is deeply trusted by patients and respected by peers alike.